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   A B S T R A C T  
  B a c k g r o u n d      Methacholine hyperresponsiveness is 
prevalent in elite athletes. Comparative studies have 
hitherto been limited to methacholine, eucapnic volun-
tary hyperpnoea and exercise. This study investigated 
airway responsiveness to these stimuli as well as to 
adenosine 5′-monophosphate (AMP) and mannitol, in 58 
cross-country ski athletes.   
  Methods     Exhaled nitric oxide concentration (F  E NO), 
spirometry and bronchial challenge in random order with 
methacholine, AMP and mannitol were consecutively 
performed on three study days in the autumn. Speciﬁ  c 
IgE to eight aeroallergens and a self-completed question-
naire about respiratory symptoms, allergy and asthmatic 
medication were also performed on day 1. Eucapnic 
voluntary hyperventilation (EVH) and ﬁ  eld exercise tests 
were randomly performed in 33 of the skiers on two 
study days in the following winter.   
  Results     Of 25 (43%) skiers with airway hyperre-
sponsiveness (AHR), 23, ﬁ  ve and three skiers were 
hyperresponsive to methacholine, AMP and mannitol, 
respectively. Methacholine hyperresponsiveness was 
more prevalent in subjects without asthma-like symp-
toms. The F  E  NO was not signiﬁ  cantly different in skiers 
with and without methacholine hyperresponsiveness. 
Four of 14 skiers with and four of 19 skiers without 
methacholine hyperresponsiveness were hyperrespon-
sive to EVH or exercise challenge. AHR to any stimulus 
was present in 16 asymptomatic and nine symptomatic 
skiers. Asthma-like symptoms were not correlated with 
AHR to any stimulus.   
  Conclusions     Methacholine hyperresponsiveness is 
more common in asymptomatic skiers and is a poor 
predictor of hyperresponsiveness to mannitol and hyper-
pnoea. The low prevalence of hyperresponsiveness to 
indirect stimuli may suggest differences in the patho-
genesis of methacholine hyperresponsiveness in elite 
s k i e r s   a n d   n o n - a t h l e t e s .       
  Highly trained athletes commonly report respi-
ratory symptoms, asthmatic medication use, 
asthma, airway hyperresponsiveness (AHR) and 
exercise-induced bronchoconstriction (EIB).  1    –    7   
  AHR to indirect stimuli, such as exercise, 
eucapnic voluntary hyperventilation (EVH), 
hypo or hypertonic aerosols and adenosine 
5′- m o n o p h o s p h a t e  ( A M P )  i s  c o n s i d e r e d  t o  b e  
more speciﬁ  c for asthma than hyperresponsive-
ness to a direct stimulus such as methacholine. 
EVH is more sensitive than sport-speciﬁ  c  ﬁ  eld 
exercise or methacholine provocation and is the 
preferred test of the Medical Commission of the 
International Olympic Committee for the detec-
tion of EIB.  8    –    10   Provocation with dry powder 
mannitol has recently been proposed as an alter-
native to EVH.  11   
  Studies comparing airway responsiveness to 
different stimuli in elite athletes have hitherto 
been restricted to methacholine, EVH and ﬁ  eld-
based or laboratory exercise.  9     12     13   In this study, 
we assessed AHR to methacholine, AMP and 
mannitol before and to EVH and a ﬁ  eld exercise 
test during the competitive season and their asso-
ciation with self-reported respiratory symptoms, 
exhaled nitric oxide concentration (F  E  NO) and 
allergic sensitisation in elite Norwegian cross-
country skiers. 
  M E T H O D S  
    Subjects and study design 
  The study population consisted of 58 non-smoking 
cross-country and biathlon ski athletes (  table 1  ). 
All subjects and parents of subjects under 18 years 
of age gave written informed consent. The study 
was approved by the Regional Ethics Committee 
in Trondheim.   
  F  E  NO, spirometry and bronchial provocation 
were consecutively performed on three study 
days in the autumn before the competitive sea-
son. The test sequence with methacholine, AMP 
and mannitol was determined by random alloca-
tion. A self-administered questionnaire on train-
ing hours, competitive experience, respiratory 
symptoms, allergy, use of asthmatic medication 
within the past year and asthma diagnosis and 
venepuncture were performed on day 1. 
  All subjects were invited 3–4 months later at 
approximately 1 month after the start of the com-
petitive season for an EVH and a sport-speciﬁ  c 
ﬁ  eld exercise test on two additional study days. 
Two subjects withdrew for personal reasons and 
23 subjects did not complete the study, because of 
a current or recent upper respiratory tract infec-
tion or training commitments.   
  Bronchial  provocation  tests 
  Subjects were instructed to refrain from vigor-
ous exercise within 4 h and using short-acting 
β  2   agonists, cromones and ipratropium within 
8 h, long-acting β  2   agonists and antihistamines 
within 48 h and leucotriene receptor antagonists 
within 96 h of testing. Caffeine-containing drinks 
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and inhaled corticosteroids were discouraged on the test day. 
Bronchial provocation was not performed within 6 weeks of 
an upper respiratory tract infection. 
  To control for diurnal variation in lung function, all tests 
were to be conducted at approximately the same time of day, 
deﬁ  ned as a maximal time difference of 90 min or less on any 
of two study days. 
  L u n g  fu n cti o n  w a s  a s s e s s e d  b y  s p ir o m e try  ( Ma s te r S c o p e  
spirometer; Erich Jaeger GmbH and Co KG, Hoechberg, 
Germany). The better of two measurements with less than 5% 
variation was recorded. Predicted normal values were based on 
reference values of Crapo   et al  .  14   
  Doubling dose increments of methacholine 2.5 mg/ml (four 
increments) and 25 mg /ml (two increments) and AMP 25 mg/ml 
(four increments) and 250 mg/ml (three increments) were 
administered from the Spira Elektro 2 automatic inhalation 
synchronised dosimeter jet nebuliser (Respiratory Care Centre, 
Hameenlinna, Finland) by a controlled tidal volume breath-
ing technique.  7     15   The cumulative dose of methacholine and 
AMP were 1814 μg and 50.5 mg, respectively. Spirometry was 
performed 90 s after each increment and 180 s after the ﬁ  nal 
increment. The test was terminated if the fall in the forced 
expiratory volume in 1 s (FEV  1  ) was 20% or greater of the FEV  1   
measured after the inhalation of 0.9% NaCl. 
  A dry powder preparation of mannitol was delivered in gela-
tine capsules containing 0, 5, 10, 20 or 40 mg.  16   Consecutive 
doses of 0, 5, 10, 20, 40, 80, 160, 160 and 160 mg to a cumu-
l a t i v e  d o s e  o f  6 3 5  m g  w e r e  a d m i n i s t e r e d  v i a  a n  i nh a l a t o r  
(Boehringer Ingelheim GmbH, Ingelheim, Germany) and a 
controlled deep inhalation to total lung capacity with 5 s of 
breathholding. Spirometry was performed 60 s after each 
dose. The test ended if the fall in FEV  1   was 15% or greater of 
the FEV  1   after inhalation of 0 mg mannitol or 635 mg had been 
inhaled. 
  For the EVH test, a dry gas mixture of 21% oxygen and 5% 
carbon dioxide in nitrogen (AGA AS, Oslo, Norway) at room 
temperature was administered through a mouthpiece attached 
to a bacterial ﬁ   lter, pneumotachograph, two-way non-
  rebreathing valve (T-Shape 2700; Hans Rudolph Inc, Shawnee, 
Kansas, USA) and two reservoir bags in series. Gas ﬂ  ow was 
regulated so that the bags were always fully inﬂ  ated. With the 
help of a metronome subjects were encouraged to achieve a 
respiratory rate of 40 breaths/min and a minute ventilation of 
30×baseline FEV  1  . The latter was measured at 30 s intervals. 
The average minute ventilation over the test duration of 8 min 
was calculated. Spirometry was performed before and at 3, 5, 
7, 10 and 20 min after challenge. 
  The sport-speciﬁ  c ﬁ  eld exercise test consisted of a ski run at 
competition intensity without a warm-up. Subjects were sent 
out in pairs whenever possible. The course was 4.7 km long 
and at a height of 118 m, increasing to a maximum height of 
186 m over sea level at 1.8 km from the start. The ambient tem-
perature varied from –13 to +2°C. Spirometry was performed 
before and at 5, 10, 15, 20 and 30 min after challenge. 
  Salbutamol 0.4 mg (Airomir Autohaler; 3M Pharma , UK) 
  was administered if the FEV  1   decline exceeded 15% after 
methacholine, AMP and mannitol and always at 20 and 30 
min, respectively, after EVH and the sport-speciﬁ  c exercise 
tests. Spirometry was performed 10 min postadministration.   
  Allergic  sensitisation 
  Serum was examined with the AlaTOP allergy screen 
(Immulite 2000; Diagnostic Products Corporation, Los Angeles, 
California, USA)   for speciﬁ  c IgE to house dust mite, cat, dog, 
horse, timothy grass and birch pollens, mugwort and cladospo-
rium. Sensitisation was deﬁ  ned as a speciﬁ  c IgE concentration of 
0.7 IU/ml or greater.   
    Exhaled nitric oxide concentration 
  F  E  NO was measured before challenge with methacholine, 
AMP and mannitol with the LR 2000 nitric oxide chemilu-
minescence analyser (Logan Research Ltd, Rochester, UK).  17   
Brieﬂ  y, subjects exhaled from total lung capacity to residual 
volume at an expiratory ﬂ  ow rate of 250 ml/s and against a tar-
get resistance of 4–5 cm water with the help of a biofeedback 
monitor. F  E  NO was the average of three measurements of the 
plateau of the exhaled nitric oxide curve.   
  D e ﬁ nitions 
  Asthma-like symptomatology was deﬁ   ned as wheeze and 
abnormal breathlessness or chest tightness, either on exertion, 
at rest or on exposure to irritants within the past year. 
  AHR to methacholine was deﬁ  ned as a provocative dose 
causing a 20% fall in FEV  1   of 1814 μg or less, AMP as a pro-
vocative dose causing a 20% fall in FEV  1   of 50.5 mg or less 
and mannitol as a provocative dose causing a 15% fall in FEV  1   
of 635 mg or less. AHR to EVH and sport-speciﬁ  c exercise 
  Table  1      Characteristics  of  study  population  
   All  subjects 
 Methacholine 
hyperresponsiveness   p  Value 
 Positive   Negative   
N (male) 58 (36) 23 (13) 35 (23) NS
Age, mean (SD), years 18.1 (1.7) 17.9 (2.0) 18.2 (1.4) NS
Height, mean (SD), cm 174.8 (8.7) 171.8 (8.7) 176.7 (8.2) 0.04
Weight, mean (SD), kg 65.7 (10.4) 63.0 (10.7) 67.5 (9.9) NS
Weekly training, mean (SD), h 11.7 (2.6) 11.3 (1.9) 12.0 (3.0) NS
Competitive experience, mean (SD), years 8.2 (2.4) 8.1 (2.7) 8.3 (2.1) NS
Self-reported allergy 16 (27%) 8 (35%) 8 (23%) NS
Positive AlaTOP screen 20 (35%) 11 (48%) 9 (26%) NS
Asthma-like symptomatology 26 (45%) 7 (30%) 19 (54%) NS
Doctor-diagnosed asthma 10 (17%) 4 (17%) 6 (17%) NS
Medication within past 12 months 19 (33%) 6 (26%) 13 (37%) NS
β   2   Agonist 11 (20%) 6 (26%) 5 (14%) NS
Inhaled corticosteroids 6 (10%) 2 (9%) 4 (11%) NS
Antihistamines 2 (3%) 0 (0%) 2 (6%) NS
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challenge was deﬁ  ned as a fall in FEV  1   over two time points of 
10% or greater from baseline. 
  Ski asthma was deﬁ   ned as the presence of asthma 
  symptomatology and AHR to methacholine.   
  S t a t i s t i c s  
  Statistical testing was performed with GraphPad Prism 4.02 
for Windows. Differences in subject characteristics were 
analysed with the Student’s t test for normally distributed 
data, Mann–Whitney U test for non-normally distributed 
data or the χ  2   test ( two-tailed p , Fisher’ s exact test when  
a p p r o p r i a t e ) .  S p i r o m e t r y  d a t a  w e r e  n o r m a l l y  d i s t r i b u t e d  
and analysed by repeated measures analysis of variance and 
Tukey’s multiple comparison test for all pairs of columns. 
F  E  NO data were not normally distributed and were analysed 
with Friedman’s test and Dunn’s multiple comparison test. 
Correlation coefﬁ   c i e n t s  w e r e  c a l c u l a t e d  u s i n g  S p e a r m a n ’ s  
rank method. Statistical signiﬁ  cance was deﬁ  ned as a p value 
of 0.05 or less.     
  R E S U L T S  
  All tests were performed without complications. For metha-
choline, AMP and mannitol tests the mean (range) interval 
was 29.5 (6–50) days. The mean maximal time difference for 
testing was 106 (0–405) min on any of two study days and 
within 90 min in 38 (66%) subjects. For EVH and ﬁ  eld exercise 
tests, the interval between tests was 9.2 (2–20) days, the mean 
maximal time difference was 149 (0–340) min and was within 
90 min in 13 (39%) subjects. 
    AHR to methacholine, AMP and mannitol 
  Twenty-ﬁ ve (43%) subjects were hyperresponsive to one of 
these stimuli. Hyperresponsiveness to methacholine was pres-
ent in 23 subjects (median (interquartile range; IQR) PD  20   FEV  1   
486 μg (342–929)) and to AMP in ﬁ  ve (8.3%) subjects (median 
(IQR) PD  20   FEV  1   35.5 mg (15.8–37.4)). Three (5.1%) subjects 
were hyperresponsive to mannitol, with individual PD  15   FEV  1   
of 315, 560 and 635 mg. 
  The response–dose ratios for AMP and mannitol were not 
signiﬁ   cantly different in skiers with and without AHR to 
methacholine (  ﬁ  gure 1  ). There was a signiﬁ  cant correlation 
between the decrements in FEV  1   during AMP and mannitol 
provocation (N=58, r  s  =0.33, p=0.011).   
  Baseline FEV  1   (mean (SD) L, % predicted (SD)) on each study 
day was within normal limits (AMP 4.04 (0.74), 103.3 (9.6); 
mannitol 4.02 (0.77)*, 102.5 (9.7); methacholine 4.12 (0.79), 
105.1 (10.3)). FEV  1   was signiﬁ  cantly lower before challenge 
with mannitol than with methacholine (*p<0.05). Forced vital 
capacity and FEV  1  /forced vital capacity ratios were also within 
normal limits (data not shown).   
    AHR to EVH and ﬁ  eld exercise 
  Average minute volume (mean (SD)) during EVH was 108.2 
(24.7) L and 77.6 (10.2) % of maximum minute ventilation. 
  Of 33 skiers, three (9%) and six (18%) skiers were hyperre-
sponsive to EVH and ﬁ  eld exercise tests, respectively. In those 
without previous methacholine hyperresponsiveness, AHR to 
either stimulus was detected in four subjects. No subject was 
positive to both tests. Of 14 (42%) skiers with methacholine 
hyperresponsiveness (median (IQR) PD  20   FEV  1   methacholine 
396.5 μg (303.5–904.5)), three were hyperresponsive to either 
test and one was hyperresponsive to both tests. 
  The area under the curve (AUC) (mean (SD) % fall FEV  1   
min) after EVH was not signiﬁ  cantly different in skiers with 
and without methacholine hyperresponsiveness (AUC  0–20   
–53 (56) vs –6 (59), p=0.061 ) or ﬁ  eld exercise test (AUC  0–30   
–110 (152) vs –19 (131), p=0.14). AHR to any of the ﬁ  ve stimuli 
was present in 20 (61%) skiers (  ﬁ  gure 2  ).     
    AHR, asthma symptomatology and doctor-diagnosed asthma 
  The relationship between asthma symptomatology and AHR 
to methacholine, AMP and mannitol is summarised in  ﬁ  gure 3  . 
Asthma-like symptomatology was not associated with AHR 
to any stimulus, with AHR to methacholine being present in 
seven (27%) and 16 (50%) skiers with and without symptoms, 
respectively. The geometric mean PD  20   FEV  1   for symptomatic 
and asymptomatic skiers was 360.0 μg (CI 167.2 to 775.3) and 
606.1 μg (CI 448.7 to 818.8), p=0.17, respectively.   
  In the methacholine-positive skiers, four reported 
doctor-  diagnosed asthma. Of these, two were on inhaled 
0.06
0.05
0.04
0.03
0.02
0.01
0.00
0.01
0.02
Negative (N=35)        Positive (N=23)
Methacholine challenge
p=0.79
B
Δ
F
E
V
1
 
(
%
)
 
/
m
g
m
a
n
n
i
t
o
l
9
−8
−7
0.55
0.30
−
−
−
−
0.05
0.20
Negative (N=35)        Positive (N=23)
Methacholine challenge
p=0.53
A
Δ
F
E
V
1
 
(
%
)
 
/
m
g
 
A
M
P
−
−
−
−
−
−
  Figure  1         Response–dose ratios for adenosine 5′-monophosphate 
(AMP) (A) and mannitol (B) in 58 skiers by hyperresponsiveness to 
methacholine. Response–dose ratio at or below stippled line indicates 
hyperresponsiveness to AMP and mannitol. Bars represent median 
values. FEV  1  , forced expiratory volume in 1 s.       
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corticosteroids and were also hyperresponsive to AMP. One of 
these skiers was also hyperresponsive to mannitol. 
  In the methacholine-negative skiers, doctor-diagnosed 
asthma was reported by six subjects. Of these, three reported 
the use of inhaled corticosteroids, one was hyperresponsive to 
mannitol and another was hyperresponsive to AMP. 
  The distribution of AHR to methacholine, AMP, mannitol, 
EVH and ﬁ  eld exercise by asthma-like symptomatology for 33 
skiers is presented in   ﬁ  gure 4  . One skier with AHR to EVH 
and ﬁ  ve skiers with AHR to exercise did not previously report 
asthma-like symptoms. One skier with AHR to both tests 
reported asthma-like symptoms.     
    Exhaled nitric oxide concentration 
  F  E  N O  w a s  m e a s u r e d  i n  4 4  s u b j e c t s  b e f o r e  c h a l l e n g e  w i t h  
mannitol, AMP and methacholine. The median (IQR) F  E  NO 
on mannitol, methacholine and AMP challenge days was 
4.1 ppb (3.5–5.4), 6.7 ppb (4.9–8.4) and 5.2 ppb (3.9–7.6) 
(p<0.001), respectively. F  E  NO was signiﬁ  cantly higher on the 
methacholine (p<0.001) and AMP (p<0.01) challenge days 
than on the mannitol challenge day. 
  F  E  NO before methacholine challenge was not signiﬁ  cantly dif-
ferent in skiers with and without hyperresponsiveness to meth-
acholine (median (IQR) 7.3 (4.3–8.6) vs 6.5 (5.2–8.2) p=0.89). 
There was no correlation between F  E  NO and the response–dose 
ratio for methacholine (N=58, r  s  =−0.074, p=0.848).   
  Allergic  sensitisation 
  Allergic sensitisation was present in 12 of 16 subjects with 
self-reported allergy, ﬁ  ve of 33 subjects without self-reported 
allergy and in three of nine subjects who were uncertain about 
their allergy status.     
  DISCUSSION 
  The airways of elite skiers clearly react in a heterogeneous 
manner in the training season in the autumn, being more 
responsive to methacholine than to AMP and mannitol. 
Methacholine hyperresponsiveness, deﬁ  ned as a PD  20   FEV  1   of 
1800 μg or less, was present in 40% (23) of skiers. By contrast, 
provocation with AMP and mannitol identiﬁ  ed AHR only in 
ﬁ  ve and three subjects, respectively. Additional provocation 
with EVH and ﬁ  eld exercise tests at 1 month into the competi-
tive season detected hyperresponsiveness in eight skiers. 
  A number of studies report a high prevalence of AHR in 
winter athletes.  4     7     18     19   This study conﬁ  rms that high preva-
lence and extends the ﬁ  nding to report that the AHR to metha-
choline was more prevalent in those not reporting asthma-like 
symptoms. Furthermore, asthmatic airway inﬂ  ammation was 
not a prerequisite for AHR to methacholine. The values for 
F  E  NO were normal and consistent with the mild AHR with 
a PD  20   of 486 μg (342–929). In the skiers with methacholine 
hyperresponsiveness, 10 (17%), eight steroid-naive skiers with 
a PD  20   FEV  1   of 400 μg or less and two skiers on inhaled cor-
ticosteroids would have satisﬁ  ed the criteria for a therapeutic 
use exemption for β  2   agonists for the 2008 Olympic Games.  20   
An additional four skiers would have qualiﬁ  ed by way of the 
hyperpnoea stimulus. 
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  Figure  2         Interrelationship of airway hyperresponsiveness to 
methacholine, adenosine 5′-monophosphate (AMP), mannitol and 
hyperpnoea (eucapnic voluntary hyperventilation and ﬁ  eld exercise 
test) in 33 skiers.       
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skiers related to self-reported asthma symptomatology (wheeze and 
abnormal breathlessness or chest tightness, either on exertion, at rest 
or on exposure to irritants within the past year).       
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  The reason for the high prevalence of AHR to methacholine 
in winter athletes is unclear. One possibility is that breathing 
large volumes of unconditioned air over long periods during 
training may cause injury to the airway epithelium,  21     22   and 
simply enhance access of the methacholine to the M3 muscar-
inic receptor on bronchial smooth muscle. The plasma exuda-
tion that follows repeated injury may lead to bronchial smooth 
muscle itself becoming more responsive through a change in 
its contractile properties.  21   A n o t h e r  p o s s i b i l i t y  i s  t h a t  t h e  
increased cholinergic tone in elite athletes  23   may increase the 
receptor sensitivity. Finally, there may have been underreport-
ing and/or reduced perception of symptoms. 
  In contrast, in the summer athletes reported by Holzer   et al    10   
and Pedersen   et al    13   there was a lower prevalence of methacho-
line AHR and a higher prevalence of AHR to indirect stimuli 
such as EVH and mannitol  11     13   The athletes studied by Holzer 
and colleagues,  10     11   however, did have a higher prevalence 
of asthma diagnosis relative to those in the current study. 
Furthermore, there is a greater frequency of allergic sensitisa-
tion in summer athletes.  24     25   In addition, there is a reduced 
likelihood of injury to the airways from the need to condition 
air when exercise is performed under warmer and more humid 
conditions of summer or in swimming pools. 
  The indirect stimuli used here are thought to induce bron-
choconstriction by the release of mast cell mediators.  26    –    29   Four 
skiers had classic allergic asthma, with AHR to either AMP 
or mannitol or both. The low prevalence of hyperresponsive-
ness to AMP in the present study corroborates our previous 
ﬁ  ndings in another population of cross-country skiers.  15   The 
prevalence of mannitol hyperresponsiveness in our study is in 
accordance with that of 9.2%, recently reported by Lund   et al    30   
in Danish elite athletes. 
  Which stimulus should be employed to assess AHR in ski-
ers with respiratory symptoms? In the present study, metha-
choline hyperresponsiveness that would satisfy International 
Olympic Committee criteria was present in only 10 of the 
skiers. For skiers with a negative methacholine test, man-
nitol provocation detected hyperresponsiveness in only one 
other skier, and EVH and ﬁ  eld exercise during the competi-
tive season identiﬁ  ed hyperresponsiveness in two other ski-
ers. In contrast, EVH was superior to methacholine in both 
elite Danish swimmers and Australian summer sports ath-
letes for diagnosing and evaluating EIB.  10     13   Stensrud   et al    18   
have demonstrated that hyperpnoea during ﬁ  eld exercise is 
less sensitive than methacholine for identifying hyperrespon-
siveness in elite skiers. Increased airway responsiveness to 
mannitol has a low prevalence in Scandinavian athletes com-
pared with the Australian athletes studied by Holzer   et al  .  11   
  Paradoxically, methacholine responsiveness is greater in ath-
letes from Scandinavia. The reasons for these differences 
are unknown, but may relate to differences in allergic sen-
sitisation or between the quantity and condition of air dur-
ing training between the two regions during several seasons. 
Although studies do not give any clear indication with regard 
to the preferred stimulus, it would be intuitive to use hyper-
pnoea as the stimulus, as symptoms in athletes are exercise 
related. If this stimulus had only been used then eight of 33 
(24%) would have been identiﬁ  ed to satisfy the International 
Olympic Committee criteria. 
  Our study was limited by the EVH and ﬁ  eld exercise tests 
being performed several months after the other tests and in 
only 57% of the original group. Although baseline FEV  1   val-
ues were not signiﬁ  cantly different on each test day (data not 
shown), selection bias may have inﬂ  uenced the prevalence of 
hyperresponsiveness to EVH and ﬁ  eld exercise. However, tests 
were performed in 24 of 26 skiers who reported asthma-like 
symptomatology at inclusion. In addition, responsiveness to 
methacholine, AMP or mannitol may have altered in the inter-
vening period. Indeed, an increase in methacholine respon-
siveness by more than twofold has been reported during the 
competitive part of the season.  31     32   However, the training 
burden is reduced during this period and a decrease in metha-
choline responsiveness cannot be excluded. Irrespective of the 
shift in responsiveness, the lower prevalence of AHR to EVH 
and a ﬁ  eld exercise test cannot be attributed to an inadequate 
stimulus. The EVH test was over 8 min instead of the conven-
tional 6 min, and the 4.7 km ski run was at competition inten-
sity and without a warm-up. We used two time points with a 
10% or greater fall for a positive test, whereas others may have 
used only one.  12   With one, the number would rise to 14. 
  In conclusion, airway responsiveness to direct and indirect 
bronchoconstrictive stimuli is heterogeneous in elite cross-
country skiers. Methacholine hyperresponsiveness is more 
prevalent in skiers without asthma-like symptoms than in 
skiers with asthma-like symptoms. The extremely low preva-
lence of hyperresponsiveness to the indirect stimuli of AMP, 
mannitol, EVH and ﬁ  eld exercise suggest a different patho-
genesis for methacholine hyperresponsiveness in elite skiers 
and non-athletes. This may be related to allergic sensitisation 
or training environment with possible consequences for the 
diagnosis and management of symptoms and AHR in these 
athletes.                               
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  What is already known on this topic 
      AHR to methacholine in winter athletes is commonly    ▶
used as objective evidence to justify the use of asthma 
medication.  
  What this study adds 
      This study demonstrates that AHR to methacholine is more    ▶
prevalent in asymptomatic than in symptomatic skiers. 
        Airway injury during training may be important in the patho-   ▶
genesis of AHR to methacholine in winter athletes.   
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